231 related articles for article (PubMed ID: 31053405)
1. The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study.
Spirtos NM; Enserro D; Homesley HD; Gibbons SK; Cella D; Morris RT; DeGeest K; Lee RB; Miller DS
Gynecol Oncol; 2019 Jul; 154(1):13-21. PubMed ID: 31053405
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study.
Homesley HD; Filiaci V; Gibbons SK; Long HJ; Cella D; Spirtos NM; Morris RT; DeGeest K; Lee R; Montag A
Gynecol Oncol; 2009 Mar; 112(3):543-52. PubMed ID: 19108877
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy for advanced endometrial cancer.
Galaal K; Al Moundhri M; Bryant A; Lopes AD; Lawrie TA
Cochrane Database Syst Rev; 2014 May; 2014(5):CD010681. PubMed ID: 24832785
[TBL] [Abstract][Full Text] [Related]
4. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
McMeekin DS; Filiaci VL; Thigpen JT; Gallion HH; Fleming GF; Rodgers WH;
Gynecol Oncol; 2007 Jul; 106(1):16-22. PubMed ID: 17574073
[TBL] [Abstract][Full Text] [Related]
5. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA
Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
[TBL] [Abstract][Full Text] [Related]
6. High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.
Reyes HD; Miecznikowski J; Gonzalez-Bosquet J; Devor EJ; Zhang Y; Thiel KW; Samuelson MI; McDonald M; Stephan JM; Hanjani P; Guntupalli S; Tewari KS; Backes F; Ramirez N; Fleming GF; Filiaci V; Birrer MJ; Leslie KK
Gynecol Oncol; 2017 Aug; 146(2):247-253. PubMed ID: 28532857
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study.
McMeekin DS; Sill MW; Walker JL; Moore KN; Waggoner SE; Thaker PH; Rizack T; Hoffman JS; Fracasso PM
Gynecol Oncol; 2015 Jul; 138(1):36-40. PubMed ID: 25958319
[TBL] [Abstract][Full Text] [Related]
8. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer.
Secord AA; Havrilesky LJ; O'Malley DM; Bae-Jump V; Fleming ND; Broadwater G; Cohn DE; Gehrig PA
Gynecol Oncol; 2009 Sep; 114(3):442-7. PubMed ID: 19560193
[TBL] [Abstract][Full Text] [Related]
9. NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer.
Viswanathan AN; Moughan J; Miller BE; Xiao Y; Jhingran A; Portelance L; Bosch WR; Matulonis UA; Horowitz NS; Mannel RS; Souhami L; Erickson BA; Winter KA; Small W; Gaffney DK
Cancer; 2015 Jul; 121(13):2156-63. PubMed ID: 25847373
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
Susumu N; Sagae S; Udagawa Y; Niwa K; Kuramoto H; Satoh S; Kudo R;
Gynecol Oncol; 2008 Jan; 108(1):226-33. PubMed ID: 17996926
[TBL] [Abstract][Full Text] [Related]
11. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
12. Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer.
Greven K; Winter K; Underhill K; Fontenesci J; Cooper J; Burke T;
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):168-73. PubMed ID: 15093913
[TBL] [Abstract][Full Text] [Related]
13. Concurrent cisplatin/radiation followed by adjuvant cisplatin/paclitaxel in treatment of patients with stage IB grade 3, IC and IIA endometrial carcinoma.
Foad I; Sharawy I; Mostafa E; Margergis M; Hussein T
J Egypt Natl Canc Inst; 2007 Jun; 19(2):163-9. PubMed ID: 19034346
[TBL] [Abstract][Full Text] [Related]
14. Sequential chemotherapy and irradiation in advanced stage endometrial cancer: A Gynecologic Oncology Group phase I trial of doxorubicin-cisplatin followed by whole abdomen irradiation.
Fowler JM; Brady WE; Grigsby PW; Cohn DE; Mannel RS; Rader JS
Gynecol Oncol; 2009 Mar; 112(3):553-7. PubMed ID: 19135232
[TBL] [Abstract][Full Text] [Related]
15. Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer.
Milgrom SA; Kollmeier MA; Abu-Rustum NR; Tew WP; Sonoda Y; Barakat RR; Alektiar KM
Gynecol Oncol; 2013 Sep; 130(3):436-40. PubMed ID: 23800696
[TBL] [Abstract][Full Text] [Related]
16. Whole abdominal radiotherapy versus combination chemotherapy with doxorubicin and cisplatin in advanced endometrial carcinoma (phase III): Gynecologic Oncology Group Study No. 122.
Randall ME; Spirtos NM; Dvoretsky P
J Natl Cancer Inst Monogr; 1995; (19):13-5. PubMed ID: 7577198
[TBL] [Abstract][Full Text] [Related]
17. [Preliminary study of sequential multi-modality adjuvant chemotherapy and radiation for advanced endometrial cancer].
Zhang G; Suo HY; Shen XY; Zhao LJ; Wang ZQ; Kong WM; Li XP; Wang JL; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2019 Feb; 54(2):103-109. PubMed ID: 30803169
[No Abstract] [Full Text] [Related]
18. Improved survival endpoints with adjuvant radiation treatment in patients with high-risk early-stage endometrial carcinoma.
Elshaikh MA; Vance S; Suri JS; Mahan M; Munkarah A
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):351-6. PubMed ID: 24411608
[TBL] [Abstract][Full Text] [Related]
19. Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation.
Klopp AH; Jhingran A; Ramondetta L; Lu K; Gershenson DM; Eifel PJ
Gynecol Oncol; 2009 Oct; 115(1):6-11. PubMed ID: 19632709
[TBL] [Abstract][Full Text] [Related]
20. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.
Leslie KK; Filiaci VL; Mallen AR; Thiel KW; Devor EJ; Moxley K; Richardson D; Mutch D; Secord AA; Tewari KS; McDonald ME; Mathews C; Cosgrove C; Dewdney S; Casablanca Y; Jackson A; Rose PG; Zhou X; McHale M; Lankes H; Levine DA; Aghajanian C
Gynecol Oncol; 2021 Apr; 161(1):113-121. PubMed ID: 33541735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
